UNSPSC 51332873: Propiomazine maleate

This classification denotes an antipsychotic agent C20H24N2OS.C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier OEY0ZC43SA, chemically known as 1-propanone, 1-(10-(2-(dimethylamino)propyl)-10h-phenothiazin-2-yl)-, (+/-), (2z)-2-butenedioate (1:1), but more generally known as propiomazine maleate, which bears US NIH Compound Identifier 5702109. European Medicines Agency schedules Propiomazine maleate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04084MIG.

Most nations, for tariff and trade purposes, schedule propiomazine maleate under HS 29343090 and SITC 51578. As of Q4 2014, PROPIOMAZINE MALEATE remains US FDA's Preferred Term for this commodity. SMILES: CCC(=O)C1CCC2C(C1)N(C3CCCCC3S2)CC(C)N(C)C.C(=C\C(=O)O)\C(=O)O.

UNSPSC 51332873 Propiomazine maleate is a Commodity code tracking a specific pharmaceutical product, but the recent state and local procurement activity under this code shows a mismatch between the nominal scope and actual buying patterns. The single recent opportunity on record—Seminole County, Florida's IFB 60459723LAS, posted June 30, 2026—solicits Naloxone and Safe Drug Deactivation Systems, which are harm-reduction and emergency-response supplies unrelated to propiomazine maleate. The county seeks 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually through a competitive bid process to support community health initiatives, with quarterly deliveries to the Seminole County Community Health Building and electronic bidding through the county's e-Procurement Portal. Bidders must include all shipping and delivery costs in their proposals, provide unit costs by line item, and meet standard compliance requirements including drug-free workplace certification and E-Verify verification.

The code shows minimal relevant recent activity. The single opportunity named above closed on July 26, 2023, predates the current date by more than three years and reflects a procurement miscoding rather than active demand for propiomazine maleate itself. Geographic activity, based on available records, is limited to Florida. Given the narrow state and local procurement footprint and the apparent mismatch between the code's pharmaceutical specification and the actual harm-reduction supplies being bought, this code does not reflect actionable market activity for business development purposes.